HIGHLIGHTS
- who: Giada De Benedittis and colleagues from the Department of Biomedicine and Prevention, Section of Genetics, University of Rome "Tor Vergata" have published the research: Impact of TRAF3IP2, IL10 and HCP5 Genetic Polymorphismsin the Response to TNF-i Treatment in Patients withPsoriatic Arthritis, in the Journal: (JOURNAL)
- what: This study aimed to investigate the potential role of the same polymorphisms in ERAP1, HCP5, IL10, MIR146A, PSORS1C1, STAT4, TNFAIP3 and TRAF3IP2 genes as predictors of efficacy of treatment in a cohort of PsA patients treated with first-line TNF-i, in particular with Etanercept (ETN) and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.